NCT06302660 (MAPLES) is a clinical trial of Breath test in Oesophageal Cancer, sponsored by Imperial College London.

Who is sponsoring NCT06302660?

NCT06302660 is sponsored by Imperial College London.

What drugs are being tested in NCT06302660?

Interventions in NCT06302660: Breath test, Saliva sample, Blood sample, Urine sample, Stool sample, Health-related Quality of life questionnaires.

What condition does NCT06302660 study?

NCT06302660 studies Oesophageal Cancer, Quality of Life, Bacterial Overgrowth.

Is NCT06302660 still recruiting?

NCT06302660 is currently active, enrolled. Last updated 27 January 2025.

Last reviewed 2025-01-27 · How we verify

NCT06302660: MAPLES

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Profiling Microbiome Associated Metabolic Pathways in Oesophageal Cancer Survivors

Active, enrolled Last updated 27 January 2025

What this trial tests

trial testing Breath test in Oesophageal Cancer in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 March 2022

Primary endpoint
1 October 2025

1 December 2025

Quick facts

Lead sponsor	Imperial College London
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	100
Start date	9 March 2022
Primary completion	1 October 2025
Estimated completion	1 December 2025
Sites	3 locations across United Kingdom

Drugs / interventions tested

Breath test
Saliva sample — full drug profile →
Blood sample — full drug profile →
Urine sample — full drug profile →
Stool sample — full drug profile →
Health-related Quality of life questionnaires

Conditions studied

Oesophageal Cancer — all drugs for Oesophageal Cancer →
Quality of Life — all drugs for Quality of Life →
Bacterial Overgrowth — all drugs for Bacterial Overgrowth →

Sponsor

Imperial College London

Who can join

Adults 18 to 90, any sex, with Oesophageal Cancer or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about long term symptoms in oesophageal cancer survivors. The main question it aims to answer is are: * Study the changes in gut bacteria by examining saliva, stool and blood. * Investigate the products of bacteria in breath to develop a non-invasive breath test to detect the changes in gut bacteria. * Develop new strategies to treat this change and trial new treatments to improve quality- of-life in oesophageal cancer survivors. Participants will attend an outpatient clinic, fasted for at least 4 hours for collection of breath, saliva, blood, urine, stool and complete validated healthy-related quality-of-life questionnaires. Researchers will compare symptomatic and asymptomatic participants to detect the changes stated above.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Crosstalk between metabolic reprogramming and microbiota: implications for cancer progression and novel therapeutic opportunities.
Li X, Jia Y, Li Y, Hei H, et al · · 2025 · cited 2× · PMID 40463381 · DOI 10.3389/fimmu.2025.1582166

Verify or expand the search:

Other trials of Breath test

Trials testing the same drug.

NCT07243262 — Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) · recruiting
NCT06285734 — Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals with Abdominal Distention · recruiting
NCT05844514 — COlorectal BReath Analysis (COBRA2) · recruiting
NCT06022588 — Chronic Mesenteric Ischemia Breath Testing · NA · completed
NCT04760639 — COVID Breath Test - Ancon · completed

Other recruiting trials for Oesophageal Cancer

Currently open trials in the same condition.

NCT06906887 — PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06364553 — Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study · NA · recruiting
NCT06440174 — Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients with Oesophageal Cancer (VALUE) · recruiting
NCT06212700 — PRIORITY-CONNECT 2 Pilot Trial · NA · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06302660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 27 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06302660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing